Mark J. Ratain to Models, Statistical
This is a "connection" page, showing publications Mark J. Ratain has written about Models, Statistical.
Connection Strength
0.450
-
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4.
Score: 0.106
-
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression. Clin Pharmacol Ther. 1994 Aug; 56(2):217-22.
Score: 0.095
-
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions. Cancer Chemother Pharmacol. 1993; 33(1):1-9.
Score: 0.085
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.085
-
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. AAPS J. 2020 03 17; 22(3):59.
Score: 0.035
-
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 03; 85(3):217-23.
Score: 0.021
-
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33.
Score: 0.016
-
A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
Score: 0.006